Access cutting-edge focal segmental glomerulosclerosis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Chicago location
Preparing your pre-screening questions…
Access focal segmental glomerulosclerosis specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related focal segmental glomerulosclerosis treatment provided free
Check if you qualify for this focal segmental glomerulosclerosis clinical trial in Chicago, IL
No-Cost Study Care
Local to Chicago
Convenient for IL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
Sponsor: Akebia Therapeutics
Yes, this clinical trial (NCT07268638) has an active research site in Chicago, IL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for focal segmental glomerulosclerosis treatment options in Chicago, IL, this clinical trial (NCT07268638) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced focal segmental glomerulosclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all focal segmental glomerulosclerosis clinical trials near you to find additional studies recruiting in your area.
See all nephrotic syndrome clinical trials recruiting in Chicago — not just this study.
Browse Nephrotic Syndrome Trials in Chicago →